Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypertrophic cardiomyopathy].

Thomas Scheffold1, Priska Binner, Jeanette Erdmann

  • 1Institut für Herz-Kreislaufforschung an der Universität, Witten/Herdecke. scheffold@herz-kreislaufforschung.de

Herz
|September 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial.

Thrombosis and haemostasis·2019
Same author

Genetic Risk Score for Coronary Disease Identifies Predispositions to Cardiovascular and Noncardiovascular Diseases.

Journal of the American College of Cardiology·2019
Same author

Contribution of Gene Regulatory Networks to Heritability of Coronary Artery Disease.

Journal of the American College of Cardiology·2019
Same author

The Clinical Impact of Psoas Muscle Cross-Sectional Area on Medium-Term Mortality After Transcatheter Aortic Valve Implantation.

Heart, lung & circulation·2019
Same author

Genetically modulated educational attainment and coronary disease risk.

European heart journal·2019
Same author

CARDIoGRAM celebrates its 10th Anniversary.

European heart journal·2019
Same journal

[Advancing cardiovascular prevention : Evidence-based design of healthy and sustainable food environments].

Herz·2026
Same journal

[Effects of air pollution on cardiovascular health].

Herz·2026
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
See all related articles

Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease often inherited. Early risk stratification for sudden death (SD) and further prospective studies are crucial for improved patient management and outcomes.

Area of Science:

  • Cardiology
  • Genetics
  • Myocardial Diseases

Context:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease affecting 0.2% of the population.
  • It is characterized by heterogeneous genetic causes, clinical manifestations, and disease progression.
  • Familial autosomal dominant inheritance is observed in approximately 60% of cases, often linked to mutations in specific genes.

Purpose:

  • To review the current understanding of hypertrophic cardiomyopathy (HCM), including its genetic basis, diagnosis, and management.
  • To highlight the heterogeneity of the disease and the need for improved risk stratification, particularly for sudden death (SD).
  • To identify gaps in current research and emphasize the necessity for large-scale prospective studies.

Summary:

Related Experiment Videos

  • HCM diagnosis relies heavily on echocardiography, with emerging roles for MRI and molecular genetic testing.
  • Prognosis is variable, influenced by hypertrophy extent and genetic mutations; SD is a significant risk in younger individuals.
  • Therapeutic strategies include medication (calcium antagonists, beta-blockers), interventional procedures (TASH/PTSMA, myectomy), and in end-stage cases, heart transplantation.

    • Impact:

    • Improved understanding of HCM's genetic underpinnings and heterogeneous nature.
    • Highlights the critical need for systematic risk stratification to prevent sudden death (SD) in HCM patients.
    • Underscores the demand for more prospective studies and registries to refine diagnostic and therapeutic guidelines for HCM.